Biotech entity
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention Activin E, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Kyle Moran, all published on August 4, 2026.
Last mentioned: Aug 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention Activin E, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Kyle Moran, all published on August 4, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 12 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Kyle Moran. Shared-story counts are live from our verified record — not editorial picks.
Wave Life Sciences presented Phase I data for WVE-007, an siRNA targeting Activin E, demonstrating up to 88% serum reduction sustained for over 7.5 months. The INLIGHT Phase IIa trial is now enrolling 160 patients across four cohorts, with a focus on BMI 35–50 and type 2 diabetes status, aiming to validate the RNA editing platform's potential for durable obesity treatment.
Kyle Moran is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
